Cover Page
Cover Page - shares | 6 Months Ended | |
Jun. 30, 2022 | Aug. 09, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2022 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q2 | |
Entity Registrant Name | iCAD, Inc. | |
Entity Central Index Key | 0000749660 | |
Current Fiscal Year End Date | --12-31 | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Trading Symbol | ICAD | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Address, State or Province | NH | |
Entity Shell Company | false | |
Entity Interactive Data Current | Yes | |
Title of 12(b) Security | Common Stock | |
Security Exchange Name | NASDAQ | |
Entity Common Stock, Shares Outstanding | 25,333,935 | |
Entity Tax Identification Number | 02-0377419 | |
Entity File Number | 001-09341 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, City or Town | Nashua | |
Entity Address, Address Line One | 98 Spit Brook Road, Suite 100 | |
Entity Address, Postal Zip Code | 03062 | |
City Area Code | 603 | |
Local Phone Number | 882-5200 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets: | ||
Cash and cash equivalents | $ 27,180 | $ 34,282 |
Trade accounts receivable, net of allowance for doubtful accounts of $778 in 2022 and $268 in 2021 | 10,171 | 8,891 |
Inventory, net | 5,001 | 4,171 |
Prepaid expenses and other current assets | 2,953 | 2,962 |
Total current assets | 45,305 | 50,306 |
Property and equipment, net of accumulated depreciation of $7,275 in 2022 and 7,106 in 2021 | 968 | 882 |
Operating lease assets | 3,102 | 1,059 |
Other assets | 55 | 899 |
Intangible assets, net of accumulated amortization of $8,820 in 2022 and $8,724 in 2021 | 587 | 683 |
Goodwill | 8,362 | 8,362 |
Total assets | 58,379 | 62,191 |
Current liabilities: | ||
Accounts payable | 2,198 | 2,779 |
Accrued and other expenses | 5,271 | 5,642 |
Lease payable—current portion | 566 | 889 |
Deferred revenue—current portion | 6,171 | 5,652 |
Total current liabilities | 14,206 | 14,962 |
Lease payable, net of current | 2,598 | 266 |
Deferred revenue, long-term portion | 581 | 441 |
Deferred tax | 4 | 5 |
Total liabilities | 17,389 | 15,674 |
Commitments and Contingencies (Note 13) | ||
Stockholders' equity: | ||
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued | ||
Common stock, $0.01 par value: authorized 60,000,000 shares; issued 25,373,858 as of June 30, 2022 and 25,326,086 as of December 31, 2021. | 254 | 253 |
Additional paid-in capital | 301,994 | 300,859 |
Accumulated deficit | (259,843) | (253,180) |
Treasury stock at cost, 185,831 shares in 2022 and 2021 | (1,415) | (1,415) |
Total stockholders' equity | 40,990 | 46,517 |
Total liabilities and stockholders' equity | $ 58,379 | $ 62,191 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Allowance for doubtful accounts on trade accounts receivable | $ 778 | $ 268 |
Property and equipment, accumulated depreciation and amortization | 7,275 | 7,106 |
Intangible assets, accumulated amortization | $ 8,820 | $ 8,724 |
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 60,000,000 | 60,000,000 |
Common stock, shares issued | 25,373,858 | 25,326,086 |
Common stock, shares outstanding | 25,188,027 | 25,140,255 |
Treasury stock, shares | 185,831 | 185,831 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Revenue: | ||||
Total revenue | $ 7,575 | $ 7,826 | $ 15,098 | $ 16,470 |
Cost of revenue: | ||||
Total cost of revenue | 2,084 | 2,288 | 4,295 | 4,643 |
Gross profit | 5,491 | 5,538 | 10,803 | 11,827 |
Operating expenses: | ||||
Engineering and product development | 2,367 | 2,268 | 4,642 | 4,460 |
Marketing and sales | 3,435 | 3,429 | 7,000 | 6,853 |
General and administrative | 2,742 | 2,652 | 5,673 | 4,803 |
Amortization and depreciation | 61 | 60 | 124 | 115 |
Total operating expenses | 8,605 | 8,409 | 17,439 | 16,231 |
Loss from operations | (3,114) | (2,871) | (6,636) | (4,404) |
Other income/ (expense): | ||||
Interest expense | 0 | (29) | (1) | (129) |
Interest income | 14 | 19 | 16 | 33 |
Other loss, net | (18) | (13) | (41) | (37) |
Loss on extinguishment of debt | (386) | 0 | (386) | |
Other expense, net | (4) | (409) | (26) | (519) |
Loss before provision for income taxes | (3,118) | (3,280) | (6,662) | (4,923) |
Provision for tax expense | 0 | 0 | (1) | 0 |
Net loss and comprehensive loss | $ (3,118) | $ (3,280) | $ (6,663) | $ (4,923) |
Net loss per share: | ||||
Basic | $ (0.12) | $ (0.13) | $ (0.26) | $ (0.2) |
Diluted | $ (0.12) | $ (0.13) | $ (0.26) | $ (0.2) |
Weighted average number of shares used in computing loss per share: | ||||
Basic | 25,185 | 24,989 | 25,172 | 24,462 |
Diluted | 25,185 | 24,989 | 25,172 | 24,462 |
Product [Member] | ||||
Revenue: | ||||
Total revenue | $ 4,475 | $ 4,552 | $ 9,035 | $ 10,109 |
Cost of revenue: | ||||
Total cost of revenue | 1,008 | 1,377 | 2,095 | 2,786 |
Service [Member] | ||||
Revenue: | ||||
Total revenue | 3,100 | 3,274 | 6,063 | 6,361 |
Cost of revenue: | ||||
Total cost of revenue | 1,001 | 832 | 2,050 | 1,699 |
Amortization and depreciation [Member] | ||||
Cost of revenue: | ||||
Total cost of revenue | $ 75 | $ 79 | $ 150 | $ 158 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] | Treasury Stock [Member] |
Beginning Balance at Dec. 31, 2020 | $ 30,525 | $ 236 | $ 273,639 | $ (241,935) | $ (1,415) |
Beginning Balance, shares at Dec. 31, 2020 | 23,694,406 | ||||
Issuance of common stock related to vesting of restricted stock | 0 | $ 0 | 0 | ||
Issuance of common stock related to vesting of restricted stock, shares | 29,166 | ||||
Issuance of common stock, net | 23,229 | $ 14 | 23,215 | ||
Issuance of common stock, net, shares | 1,393,738 | ||||
Issuance of common stock pursuant to stock option plans | 636 | $ 1 | 635 | ||
Issuance of common stock pursuant to stock option plans, shares | 83,748 | ||||
Issuance of common stock pursuant Employee Stock Purchase Plan | 114 | 114 | |||
Issuance of common stock pursuant Employee Stock Purchase Plan, shares | 12,244 | ||||
Stock-based compensation | 1,446 | 1,446 | |||
Net loss | (4,923) | (4,923) | |||
Ending Balance at Jun. 30, 2021 | 51,027 | $ 251 | 299,049 | (246,858) | (1,415) |
Ending Balance, shares at Jun. 30, 2021 | 25,213,302 | ||||
Beginning Balance at Mar. 31, 2021 | 53,364 | $ 251 | 298,106 | (243,578) | (1,415) |
Beginning Balance, shares at Mar. 31, 2021 | 25,143,432 | ||||
Issuance of common stock related to vesting of restricted stock | $ 0 | 0 | |||
Issuance of common stock related to vesting of restricted stock, shares | 9,166 | ||||
Issuance of common stock, net | 365 | $ 0 | 365 | ||
Issuance of common stock, net, shares | 54,814 | ||||
Issuance of common stock pursuant to stock option plans | $ 0 | 0 | |||
Issuance of common stock pursuant to stock option plans, shares | 0 | ||||
Issuance of common stock pursuant Employee Stock Purchase Plan | 67 | 67 | |||
Issuance of common stock pursuant Employee Stock Purchase Plan, shares | 5,890 | ||||
Stock-based compensation | 511 | 511 | |||
Net loss | (3,280) | (3,280) | |||
Ending Balance at Jun. 30, 2021 | 51,027 | $ 251 | 299,049 | (246,858) | (1,415) |
Ending Balance, shares at Jun. 30, 2021 | 25,213,302 | ||||
Beginning Balance at Dec. 31, 2021 | 46,517 | $ 253 | 300,859 | (253,180) | (1,415) |
Beginning Balance, shares at Dec. 31, 2021 | 25,326,086 | ||||
Issuance of common stock related to vesting of restricted stock | 0 | $ 0 | 0 | ||
Issuance of common stock related to vesting of restricted stock, shares | 875 | ||||
Issuance of common stock pursuant to stock option plans | $ 79 | $ 1 | 78 | ||
Issuance of common stock pursuant to stock option plans, shares | 28,833 | 28,833 | |||
Issuance of common stock pursuant Employee Stock Purchase Plan | $ 93 | $ 0 | 93 | ||
Issuance of common stock pursuant Employee Stock Purchase Plan, shares | 18,064 | ||||
Stock-based compensation | 964 | 964 | |||
Net loss | (6,663) | (6,663) | |||
Ending Balance at Jun. 30, 2022 | 40,990 | $ 254 | 301,994 | (259,843) | (1,415) |
Ending Balance, shares at Jun. 30, 2022 | 25,373,858 | ||||
Beginning Balance at Mar. 31, 2022 | 43,753 | $ 253 | 301,640 | (256,725) | (1,415) |
Beginning Balance, shares at Mar. 31, 2022 | 25,359,175 | ||||
Issuance of common stock related to vesting of restricted stock | 0 | $ 0 | 0 | ||
Issuance of common stock related to vesting of restricted stock, shares | 0 | ||||
Issuance of common stock pursuant to stock option plans | 13 | $ 1 | 12 | ||
Issuance of common stock pursuant to stock option plans, shares | 6,000 | ||||
Issuance of common stock pursuant Employee Stock Purchase Plan | 33 | $ 0 | 33 | ||
Issuance of common stock pursuant Employee Stock Purchase Plan, shares | 8,683 | ||||
Stock-based compensation | 309 | 309 | |||
Net loss | (3,118) | (3,118) | |||
Ending Balance at Jun. 30, 2022 | $ 40,990 | $ 254 | $ 301,994 | $ (259,843) | $ (1,415) |
Ending Balance, shares at Jun. 30, 2022 | 25,373,858 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Cash flow from operating activities: | ||
Net loss | $ (6,663) | $ (4,923) |
Adjustments to reconcile net loss to net cash used for operating activities: | ||
Amortization | 105 | 115 |
Depreciation | 169 | 157 |
Non-cash lease expense | 391 | 388 |
Bad debt provision | 510 | (3) |
Stock-based compensation | 964 | 1,446 |
Amortization of debt discount and debt costs | 0 | 17 |
Loss on extinguishment of debt | 0 | 386 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (1,790) | (924) |
Inventory | (830) | 284 |
Prepaid and other assets | 853 | 122 |
Accounts payable | (581) | (1,829) |
Accrued and other expenses | (371) | (432) |
Lease liabilities | (425) | (304) |
Deferred revenue | 659 | (77) |
Total adjustments | (346) | (654) |
Net cash used for operating activities | (7,009) | (5,577) |
Cash flow from investing activities: | ||
Additions to patents, technology and other | (10) | 0 |
Additions to property and equipment | (255) | (336) |
Net cash used for investing activities | (265) | (336) |
Cash flow from financing activities: | ||
Proceeds from option exercises pursuant to stock option plans | 79 | 636 |
Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plans | 93 | 114 |
Proceeds from issuance of common stock, net | 0 | 23,229 |
Issuance of stock upon conversion of debentures | 0 | (7,363) |
Net cash provided by financing activities | 172 | 16,616 |
(Decrease) increase in cash and cash equivalents | (7,102) | 10,703 |
Cash and cash equivalents, beginning of period | 34,282 | 27,186 |
Cash and cash equivalents, end of period | 27,180 | 37,889 |
Supplemental disclosure of cash flow information: | ||
Interest paid | 9 | 92 |
Amendment to right-of-use assets obtained in exchange for operating lease liabilities | $ 2,434 | $ 0 |
Basis of Presentation and Signi
Basis of Presentation and Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Significant Accounting Policies | Note 1 – Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at June 30, 2022, the results of operations of the Company for the three and six months ended June 30, 2022 and 2021, cash flows of the Company for the six months ended June 30, 2022 and 2021, and stockholders’ equity for the Company for the three and six months ended June 30, 2022 and 2021. Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K Principles of Consolidation and Business Segments The condensed consolidated financial statements include the accounts of iCAD, Inc. and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, iCAD France, LLC and iCAD Italy, LLC,. All material inter-company transactions and balances have been eliminated in consolidation. The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products for the detection of cancer. The Therapy segment consists of radiation therapy (“Xoft”, “Axxent”) products for the treatment of certain cancers. Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19 COVID-19. COVID-19 It is currently not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to prior levels. The COVID-19 COVID-19 COVID-19; COVID-19 Although the Company has seen some impact to trade accounts receivable losses in the three and six months ended June 30, 2022 due to disruptions associated with the current COVID-19 COVID-19 COVID-19 Economic, civil, military and political uncertainty may arise or increase in regions where the Company operates or derives revenue. Further, countries from which the Company derives revenue may experience military action and/or civil and political unrest; may be subject to government export controls, economic sanctions, embargoes, or trade restrictions; and experience currency, inflation, and interest rate uncertainties. For the fiscal year ended 2021, approximately 8.6% of the Company’s total revenue and approximately 39.0% of the Company’s export revenue was derived from customers located in Europe. In late February 2022, Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region is likely. The aggregate impact to Eastern Europe and Europe as a whole, as well as actions taken by other countries, including new and stricter sanctions by the United States, Canada, the United Kingdom, the European Union, and other countries and organizations against officials, individuals, regions, and industries in Russia, Belarus and Ukraine, and each country’s potential response to such sanctions, tensions and military actions, is not knowable at this time, and could have a material adverse effect on the Company, its business and operations. Any such material adverse effect from the conflict and enhanced sanctions activity may disrupt the Company’s sales to customers in the region. Prolonged unfavorable economic conditions or uncertainty may have an adverse effect on the Company’s sales and profitability. Recently Adopted Accounting Pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, 470-20) 815-40)—Accounting 2020-06”).” 2020-06 Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, 2016-13”), 2016-13 2016-13 2016-13 2016-13 |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 2 – Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurement and Disclosures” (“ASC 820”), which defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The Company applies the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, which are the following: • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value The assigned level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Money market funds included in cash and cash equivalents in the accompanying consolidated balance sheet are considered a Level 1 measurement as they are valued at quoted market prices in active markets. The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy: Fair Value Measurements as of June 30, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 22,047 $ — $ — $ 22,047 Total Assets $ 22,047 $ — $ — $ 22,047 Fair Value Measurements as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 $ — $ — $ 30,573 Total Assets $ 30,573 $ — $ — $ 30,573 There were no Level 3 instruments measured at fair value as of June 30, 2022 or December 31, 2021. |
Revenue
Revenue | 6 Months Ended |
Jun. 30, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenue | Note 3 - Revenue Revenue Recognition Revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration which the Company expects to be entitled to receive in exchange for these goods or services and excludes any sales incentives or taxes collected from customers which are subsequently remitted to government authorities. Disaggregation of Revenue The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments. Three months ended June 30, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,467 $ 1,008 $ 4,475 Service contracts 1,822 361 2,183 Supply and source usage agreements — 367 367 Disposable applicators — 463 463 Other — 87 87 $ 5,289 $ 2,286 $ 7,575 Timing of Revenue Recognition Goods transferred at a point in time $ 3,455 $ 1,547 $ 5,002 Services transferred over time 1,834 739 2,573 $ 5,289 $ 2,286 $ 7,575 Sales Channels Direct sales force $ 3,505 $ 703 $ 4,208 OEM partners 1,784 — 1,784 Channel partners — 1,583 1,583 $ 5,289 $ 2,286 $ 7,575 Six months ended June 30, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 7,330 $ 1,705 $ 9,035 Service contracts 3,479 747 4,226 Supply and source usage agreements — 780 780 Disposable applicators — 878 878 Other — 179 179 $ 10,809 $ 4,289 $ 15,098 Timing of Revenue Recognition Goods transferred at a point in time $ 7,335 $ 2,812 $ 10,147 Services transferred over time 3,474 1,477 4,951 $10,809 $4,289 $15,098 Sales Channels Direct sales force $ 6,399 $ 1,519 $ 7,918 OEM partners 4,410 — 4,410 Channel partners — 2,770 2,770 $ 10,809 $ 4,289 $ 15,098 Three months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,164 $ 2,119 $ 5,283 Service contracts 1,625 371 1,996 Supply and source usage agreements — 529 529 Other — 18 18 $ 4,789 $ 3,037 $ 7,826 Timing of Revenue Recognition Goods transferred at a point in time $ 3,164 $ 2,136 $ 5,300 Services transferred over time 1,625 901 2,526 $ 4,789 $ 3,037 $ 7,826 Sales Channels Direct sales force $ 3,188 $ 1,252 $ 4,440 OEM partners 1,601 — 1,601 Channel partners — 1,785 1,785 $ 4,789 $ 3,037 $ 7,826 Six months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 7,325 $ 4,222 $ 11,547 Service contracts 3,183 711 3,894 Supply and source usage agreements — 1,010 1,010 Other — 19 19 $ 10,508 $ 5,962 $ 16,470 Timing of Revenue Recognition Goods transferred at a point in time $ 7,325 $ 4,240 $ 11,565 Services transferred over time 3,183 1,722 4,905 $ 10,508 $ 5,962 $ 16,470 Sales Channels Direct sales force $ 7,063 $ 1,926 $ 8,989 OEM partners 3,445 — 3,445 Channel partners — 4,036 4,036 $ 10,508 $ 5,962 $ 16,470 Products. Service Sources and Source Usage Agreements Disposable applicators Other. Contract Balances Contract liabilities are a component of deferred revenue, current contract assets are a component of prepaid and other assets and non-current non-current Contract balances Balance at Balance at June 30, 2022 December 31, 2021 Receivables, which are included in ‘Trade accounts receivable’ $ 10,171 $ 8,891 Current contract assets, which are included in “Prepaid and other assets” $ 1,399 $ 1,895 Non-current $ — $ 844 Contract liabilities, which are included in “Deferred revenue” $ 6,752 $ 6,093 Timing of revenue recognition may differ from timing of invoicing of customers. The Company records a receivable when revenue is recognized prior to receipt of cash payment and the Company has the unconditional right to such consideration, or unearned revenue when cash payments are received or due in advance of performance. For multi-year agreements, the Company generally invoices customers annually at the beginning of each annual service period. The Company records net contract assets or contract liabilities on a contract-by-contract non-current non-current Changes in deferred revenue from contracts with customers were as follows: Six Months Ended June 30, 2022 Balance at beginning of period $ 6,093 Deferral of revenue 6,333 Recognition of deferred revenue (5,674 ) Balance at end of period $ 6,752 The Company expects to recognize estimated revenues related to performance obligation that are unsatisfied (or partially satisfied) in the amounts of approximately $4.6 million in 2022, $3.5 million in 2023, $1.3 million in 2024, $1.1 million in 2025 and $0.1 million thereafter. |
Net Loss per Common Share
Net Loss per Common Share | 6 Months Ended |
Jun. 30, 2022 | |
Earnings Per Share [Abstract] | |
Net Loss per Common Share | Note 4 – Net Loss per Common Share The Company’s basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. A summary of the Company’s calculation of net loss per share is as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 202 1 Net loss $ (3,118 ) $ (3,280 ) $ (6,663 ) $ (4,923 ) Shares used in the calculation of basic and diluted net loss per share 25,185 24,989 25,172 24,462 Net loss per share - basic and diluted $ (0.12 ) $ (0.13 ) $ (0.26 ) $ (0.20 ) The shares of the Company’s common stock issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: June 30, 2022 2021 Stock options 1,819,897 2,176,607 Restricted stock — 21,613 Total 1,819,897 2,198,220 |
Inventories
Inventories | 6 Months Ended |
Jun. 30, 2022 | |
Inventory Disclosure [Abstract] | |
Inventories | Note 5 – Inventories The Company values its inventory at the lower of cost or net realizable value. Cost includes materials, labor, and manufacturing overhead and is determined using the first-in, first-out June 30, 2022 December 31, 2021 Raw materials $ 2,549 $ 2,962 Work in process 218 173 Finished Goods 2,503 1,279 Inventory Gross 5,270 4,414 Inventory Reserve (269 ) (243 ) Inventory Net $ 5,001 $ 4,171 |
Goodwill
Goodwill | 6 Months Ended |
Jun. 30, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill | Note 6 - Goodwill The Company tests goodwill for impairment on an annual basis and between annual tests if events and circumstances indicate it is more likely than not that the fair value of the reporting unit is less than its carrying value. There were no impairment indicators present as of June 30, 2022. Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. |
Long-lived assets
Long-lived assets | 6 Months Ended |
Jun. 30, 2022 | |
Property, Plant and Equipment [Abstract] | |
Long-lived assets | Note 7 – Long-lived Assets The Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than its carrying value. There is no set interval or frequency for recoverability evaluation. Rather, the determination of when, if at all, an asset (or asset group) is evaluated for recoverability is based on “events and circumstances.” The following factors are examples of events or changes in circumstances that indicate the carrying amount of an asset (or asset group) may not be recoverable and thus is to be evaluated for recoverability. • A significant decrease in the market price of a long-lived asset (or asset group); • A significant adverse change in the extent or manner in which a long-lived asset (or asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (or asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived • A current operating period, or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (or asset group). The Company determined there were no such triggering events in the period ended June 30, 2022. |
Leases Commitments
Leases Commitments | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Lease Commitments | Note 8 – Lease Commitments Per ASC 842, the Company determines if an arrangement contains a lease at inception. A lease is an operating or financing contract, or part of a contract, that conveys the right to control the use of an identified tangible asset for a period of time in exchange for consideration. At lease inception, the Company recognizes a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for lease incentives. In determining the present value of the lease payments, the Company uses its incremental borrowing rate, determined by estimating the Company’s applicable, fully collateralized borrowing rate, with adjustment as appropriate for lease term. The lease term at the lease commencement date is determined based on the non-cancellable Assumptions that we made at the commencement date of each lease are re-evaluated In May of 2022, the Company entered into an agreement to amend its Irvine operating lease (the “Irvine Amendment”). The Irvine Amendment extended the lease term of the premises by 5 years, or until March of 2028. Fixed monthly rent for the space will be incurred at a rate of $2.10 per square foot per year beginning in April 2023, subject to annual increases of $.06 per square foot in 2025 and 2026 as well as annual increases of $.07 per square foot in 2027 and 2028. The Irvine Amendment includes a five-year option to extend the term. Upon the execution of the Irvine Amendment, which was deemed to be a lease modification, the Company re-evaluated C right-of-use right-of-use Right-of-use non-lease non-lease ASC 842 includes a number of reassessment and re-measurement requirements for lessees based on certain triggering events or conditions. There were no impairment indicators identified during the three and six months ended June 30, 2022 that would require impairment testing of the Company’s right-of-use assets. Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease non-lease Components of Leases: The Company has leases for office space and office equipment. The leases expire at various dates through 2028. Three Months Six Months Ended June 30, Ended June 30, Lease Cost Classification 2022 2022 Operating lease cost - Right of Use Asset Operating expenses $ 215 $ 430 Other information related to leases was as follows: Three Months Six Months Ended June 30, Ended June 30, 2022 202 2 Cash paid from operating cash flows for operating leases $ 236 $ 465 As of June 30, Weighted-average remaining lease term of operating leases (year s 5.7 Weighted-average discount rate for operating leases 7.4 % Maturity of the Company’s lease liabilities as of June 30, 2022 was as follows: 2022 $ 467 2023 611 2024 642 2025 644 2026 664 2027 684 2028 172 Total lease payments 3,884 Less: imputed interest (720 ) Total lease liabilities 3,164 Less: current portion of lease liabilities (566 ) Long-term lease liabilities $ 2,598 |
Notes Payable
Notes Payable | 6 Months Ended |
Jun. 30, 2022 | |
Debt Disclosure [Abstract] | |
Notes Payable | Note 9 – Notes Payable (a) Loan and Security Agreement – Western Alliance Bank On March 30, 2020, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Western Alliance Bank (the “Bank”) that provided an initial term loan (“Term Loan”) facility of $7.0 million and a $5.0 million revolving line of credit. Obligations to the Bank under the Loan Agreement were secured by a first priority security interest in the Company’s assets, except for certain permitted liens that have priority to the Bank’s security interest by operation of law. On April 27, 2021, the Company repaid its obligations in the aggregate amount of $7,354,283 and terminated the Loan Agreement with the Bank, and the Company’s collateral securing the facility was released. The Company accounted for this repayment and retirement as an extinguishment of the Loan Agreement. The Company recorded a loss on extinguishment of approximately $386,000 at that time related to the repayment and retirement of the Loan Agreement. The loss on extinguishment was composed of approximately $140,000 for a prepayment fee, $122,000 for the unaccrued final payment, $65,000 termination and other fees, and $58,000 for the unamortized discount and other closing costs from origination of the loan. The following amounts are included in interest expense related to the Loan Agreement in the Company’s consolidated statement of operations for the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cash interest expense $ — $ 27 $ — $ 107 Accrual of notes payable final payment — 2 — 9 Amortization of debt costs — — — 13 Total interest expense $ — $ 29 $ — $ 129 |
Stockholders Equity
Stockholders Equity | 6 Months Ended |
Jun. 30, 2022 | |
Federal Home Loan Banks [Abstract] | |
Stockholders Equity | Note 10 – Stockholders Equity (a) Financing Activity On March 2, 2021, the Company entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters thereto, in connection with an underwritten public offering of 1,393,738 shares of the Company’s common stock at an offering price of $18.00 per share. The Offering closed on March 5, 2021 for gross proceeds of approximately $25.1 million and net proceeds of approximately $23.2 million to the Company. (b) Stock-Based Compensation The Company granted options to purchase 85,000 and 760,000 shares of the Company’s stock during the three and six months ended June 30, 2022 respectively. The full amount of options were granted in the first six months of 2022. The Company’s stock-based compensation expense, including options and restricted stock by category is as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of revenue $ 1 $ 2 $ 1 $ 16 Engineering and product development 70 58 138 208 Marketing and sales 109 128 308 481 General and administrative 129 323 517 741 $ 309 $ 511 $ 964 $ 1446 As of June 30, 2022, there was approximately $2.8 million of total unrecognized compensation cost related to unvested options and restricted stock. That cost is expected to be recognized over a weighted average period of 1.92 years. Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Average risk-free interest rate 2.56% N/A 1.90% 0.20% Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility 69.7% to 70.5% N/A 66.3% to 70.5% 66.0% to 66.0% Weighted average exercise price $5.19 N/A $5.22 $18.00 Weighted average fair value $1.72 N/A $2.46 $8.37 The Company’s 2022 and 2021 average expected volatility and average expected life is based on the average of the Company’s historical information. The risk-free rate is based on the rate of U.S. Treasury zero-coupon The Company did not grant any shares of restricted stock during the three-months ended June 30, 2022 or 2021. The Company granted 0 and 22,488 shares of restricted stock during the six months ended June 30, 2022 and 2021, respectively. The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from the grant date. All of the Company’s restricted stock grants in 2021 had time-based vesting requirements. The grant date fair value for restricted stock awards is based on the quoted market value of Company stock on the grant date. A summary of stock option activity for all stock option plans for the period ended June 30, 2022 is as follows: Number of Weighted Average Intrinsic Outstanding as of December 31, 2021 2,486,511 $ 9.27 $ 3,820 Granted 760,000 $ 5.22 $ 3 Exercised (28,833 ) $ 2.74 $ 75 Cancelled (479,797 ) $ 12.33 $ — Outstanding as of June 30, 2022 2,737,881 $ 7.68 $ 833 Options Exercisable as of December 31, 2021 1,619,855 $ 6.47 $ 3,730 Options Exercisable as of June 30, 2022 1,819,897 $ 7.44 $ 830 The Company issued 6,000 and 28,833 shares of common stock upon the exercise of outstanding stock options in the three and six months ended June 30 30 There were no restricted shares that vested in the three and six months ended June 30, 2022. Employee Stock Purchase Plan In December 2019, the Company’s Board of Directors adopted, and the stockholders approved the 2019 Employee Stock Purchase Plan (“ESPP”), effective January 1, 2020. The ESPP provides for the issuance of up 950,000 shares of common stock, subject to adjustment in the event of a stock split, stock dividend or other change in the Company’s capitalization. The ESPP may be terminated or amended by the Board of Directors at any time. Certain amendments to the ESPP require stockholder approval. Substantially all of the Company’s employees whose customary employment is for more than 20 hours a week are eligible to participate in the ESPP. Any employee who owns 5% or more of the voting power or value of the Company’s shares of common stock is not eligible to purchase shares under the ESPP. Any eligible employee can enroll in the Plan as of the beginning of a respective quarterly accumulation period. Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. The Company issued 8,683 and 18,064 shares under the ESPP in the three and six months ended June 30, 2022 respectively. The Company recorded approximately $12,000 and $22,000 of stock-based compensation expense pursuant to ESPP for the three and six months ended June 30, 2022, respectively. The next accumulation period under the ESPP commenced on March 31, 2022 and ended on June 30, 2022, and the related shares purchased by the participants were issued in July 2022. As of June 30, 2022, the Company recorded a liability of approximately $34,000 related to employee withholdings in connection with the ESPP accumulation period ended June 30, 2022, which was included as a component of accrued expenses and other current liabilities. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 11 - Income Taxes The Company had no material unrecognized tax benefits and a deferred tax liability of approximately $5,100 related to tax amortizable goodwill at June 30, 2022. No other adjustments were required under ASC 740, “Income Taxes.” The Company does not expect that its unrecognized tax benefits will materially increase within the next 12 months. The Company did not recognize any interest or penalties related to uncertain tax positions at June 30, 2022. The Company files United States federal income tax returns and income tax returns in various states and local jurisdictions. The Company’s three preceding tax years remain subject to examination by federal and state tax authorities. In addition, because the Company has net operating loss carry-forwards, the Internal Revenue Service and state jurisdictions are permitted to audit earlier years and propose adjustments up to the amount of net operating loss generated in those years. The Company is not currently under examination by any federal or state jurisdiction for any tax years. |
Segment Reporting
Segment Reporting | 6 Months Ended |
Jun. 30, 2022 | |
Segment Reporting [Abstract] | |
Segment Reporting | Note 12 – Segment Reporting Operating segments are the components of the Company’s business for which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is the chief executive officer. The Company’s operating segments are generally organized by the type of product or service offered and by geography. Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments: Detection and Therapy. The Detection segment consists of the Company’s advanced image analysis and workflow products, and the Therapy segment consists of the Company’s radiation therapy products, and related services. The primary factors used by the Company’s CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring The Company does not track its assets by operating segment and the CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Segment revenues: Detection $ 5,289 $ 4,789 $ 10,809 $ 10,508 Therapy 2,286 3,037 4,289 5,962 Total Revenue $ 7,575 $ 7,826 $ 15,098 $ 16,470 Segment gross profit: Detection $ 4,554 $ 4,005 $ 9,215 $ 8,730 Therapy 937 1,533 1,588 3,097 Segment gross profit $ 5,491 $ 5,538 $ 10,803 $ 11,827 Segment operating income (loss): Detection $ 446 $ 52 $ 1,068 $ 993 Therapy (797 ) (250 ) (2,006 ) (562 ) Segment operating income (loss): $ (351 ) $ (198 ) $ (938 ) $ 431 General, administrative, depreciation and amortization expense $ (2,763 ) $ (2,673 ) $ (5,698 ) $ (4,835 ) Interest expens e — (29 ) (1 ) (129 ) Interest income 14 19 16 33 Other expense (18 ) (13 ) (41 ) (37 ) Loss on extinguishment of debt — (386 ) — (386 ) Loss before income tax $ (3,118 ) $ (3,280 ) $ (6,662 ) $ (4,923 ) |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 13 – Commitments and Contingencies Other Commitments The Company is obligated to pay approximately $5.1 million for firm purchase obligations to suppliers for future product and service deliverables and $0.2 million for minimum royalty obligations. Litigation The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. However, should the Company fail to prevail in any legal matter or should several legal matters be resolved against the Company in the same reporting period, such matters could have a material adverse effect on the Company’s operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, “Contingencies.” Legal costs are expensed as incurred. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 14 – Subsequent Events The Company has evaluated events and transactions subsequent to the balance sheet date to the date of the filing and is not aware of any events or transactions that occurred subsequent to the balance sheet date that would require recognition or disclosure in the consolidated financial statements. |
Basis of Presentation and Sig_2
Basis of Presentation and Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Segment Reporting [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying condensed consolidated financial statements of iCAD, Inc. and its subsidiaries (together “iCAD” or the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting period and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. In the opinion of the Company’s management, these unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position of the Company at June 30, 2022, the results of operations of the Company for the three and six months ended June 30, 2022 and 2021, cash flows of the Company for the six months ended June 30, 2022 and 2021, and stockholders’ equity for the Company for the three and six months ended June 30, 2022 and 2021. Although the Company believes that the disclosures made in these interim financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K |
Principles of Consolidation and Business Segments | Principles of Consolidation and Business Segments The condensed consolidated financial statements include the accounts of iCAD, Inc. and its wholly owned subsidiaries: Xoft, Inc., Xoft Solutions, LLC, iCAD France, LLC and iCAD Italy, LLC,. All material inter-company transactions and balances have been eliminated in consolidation. The Company reports the results of two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products for the detection of cancer. The Therapy segment consists of radiation therapy (“Xoft”, “Axxent”) products for the treatment of certain cancers. |
Risk and Uncertainty | Risk and Uncertainty On March 12, 2020, the World Health Organization declared COVID-19 COVID-19 COVID-19. COVID-19 It is currently not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to prior levels. The COVID-19 COVID-19 COVID-19; COVID-19 Although the Company has seen some impact to trade accounts receivable losses in the three and six months ended June 30, 2022 due to disruptions associated with the current COVID-19 COVID-19 COVID-19 Economic, civil, military and political uncertainty may arise or increase in regions where the Company operates or derives revenue. Further, countries from which the Company derives revenue may experience military action and/or civil and political unrest; may be subject to government export controls, economic sanctions, embargoes, or trade restrictions; and experience currency, inflation, and interest rate uncertainties. For the fiscal year ended 2021, approximately 8.6% of the Company’s total revenue and approximately 39.0% of the Company’s export revenue was derived from customers located in Europe. In late February 2022, Russian military forces launched significant military action against Ukraine. Sustained conflict and disruption in the region is likely. The aggregate impact to Eastern Europe and Europe as a whole, as well as actions taken by other countries, including new and stricter sanctions by the United States, Canada, the United Kingdom, the European Union, and other countries and organizations against officials, individuals, regions, and industries in Russia, Belarus and Ukraine, and each country’s potential response to such sanctions, tensions and military actions, is not knowable at this time, and could have a material adverse effect on the Company, its business and operations. Any such material adverse effect from the conflict and enhanced sanctions activity may disrupt the Company’s sales to customers in the region. Prolonged unfavorable economic conditions or uncertainty may have an adverse effect on the Company’s sales and profitability. |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements On January 1, 2022, the Company adopted ASU No. 2020-06, 470-20) 815-40)—Accounting 2020-06”).” 2020-06 Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, 2016-13”), 2016-13 2016-13 2016-13 2016-13 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Fair Value Disclosures [Abstract] | |
Assets and Liabilities which are Measured at Fair Value on a Recurring Basis | The following table sets forth the Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy: Fair Value Measurements as of June 30, 2022 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 22,047 $ — $ — $ 22,047 Total Assets $ 22,047 $ — $ — $ 22,047 Fair Value Measurements as of December 31, 2021 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 30,573 $ — $ — $ 30,573 Total Assets $ 30,573 $ — $ — $ 30,573 |
Revenue (Tables)
Revenue (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments | The following tables presents the Company’s revenues disaggregated by major good or service line, timing of revenue recognition, and sales channel, reconciled to its reportable segments. Three months ended June 30, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,467 $ 1,008 $ 4,475 Service contracts 1,822 361 2,183 Supply and source usage agreements — 367 367 Disposable applicators — 463 463 Other — 87 87 $ 5,289 $ 2,286 $ 7,575 Timing of Revenue Recognition Goods transferred at a point in time $ 3,455 $ 1,547 $ 5,002 Services transferred over time 1,834 739 2,573 $ 5,289 $ 2,286 $ 7,575 Sales Channels Direct sales force $ 3,505 $ 703 $ 4,208 OEM partners 1,784 — 1,784 Channel partners — 1,583 1,583 $ 5,289 $ 2,286 $ 7,575 Six months ended June 30, 2022 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 7,330 $ 1,705 $ 9,035 Service contracts 3,479 747 4,226 Supply and source usage agreements — 780 780 Disposable applicators — 878 878 Other — 179 179 $ 10,809 $ 4,289 $ 15,098 Timing of Revenue Recognition Goods transferred at a point in time $ 7,335 $ 2,812 $ 10,147 Services transferred over time 3,474 1,477 4,951 $10,809 $4,289 $15,098 Sales Channels Direct sales force $ 6,399 $ 1,519 $ 7,918 OEM partners 4,410 — 4,410 Channel partners — 2,770 2,770 $ 10,809 $ 4,289 $ 15,098 Three months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 3,164 $ 2,119 $ 5,283 Service contracts 1,625 371 1,996 Supply and source usage agreements — 529 529 Other — 18 18 $ 4,789 $ 3,037 $ 7,826 Timing of Revenue Recognition Goods transferred at a point in time $ 3,164 $ 2,136 $ 5,300 Services transferred over time 1,625 901 2,526 $ 4,789 $ 3,037 $ 7,826 Sales Channels Direct sales force $ 3,188 $ 1,252 $ 4,440 OEM partners 1,601 — 1,601 Channel partners — 1,785 1,785 $ 4,789 $ 3,037 $ 7,826 Six months ended June 30, 2021 Reportable Segments Detection Therapy Total Major Goods/Service Lines Products $ 7,325 $ 4,222 $ 11,547 Service contracts 3,183 711 3,894 Supply and source usage agreements — 1,010 1,010 Other — 19 19 $ 10,508 $ 5,962 $ 16,470 Timing of Revenue Recognition Goods transferred at a point in time $ 7,325 $ 4,240 $ 11,565 Services transferred over time 3,183 1,722 4,905 $ 10,508 $ 5,962 $ 16,470 Sales Channels Direct sales force $ 7,063 $ 1,926 $ 8,989 OEM partners 3,445 — 3,445 Channel partners — 4,036 4,036 $ 10,508 $ 5,962 $ 16,470 |
Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers | The following table provides information about receivables, current and non-current Balance at Balance at June 30, 2022 December 31, 2021 Receivables, which are included in ‘Trade accounts receivable’ $ 10,171 $ 8,891 Current contract assets, which are included in “Prepaid and other assets” $ 1,399 $ 1,895 Non-current $ — $ 844 Contract liabilities, which are included in “Deferred revenue” $ 6,752 $ 6,093 |
Summary of Changes in Deferred Revenue | Changes in deferred revenue from contracts with customers were as follows: Six Months Ended June 30, 2022 Balance at beginning of period $ 6,093 Deferral of revenue 6,333 Recognition of deferred revenue (5,674 ) Balance at end of period $ 6,752 |
Net Loss per Common Share (Tabl
Net Loss per Common Share (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Earnings Per Share [Abstract] | |
Calculation of Net Loss Per Share | A summary of the Company’s calculation of net loss per share is as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 202 1 Net loss $ (3,118 ) $ (3,280 ) $ (6,663 ) $ (4,923 ) Shares used in the calculation of basic and diluted net loss per share 25,185 24,989 25,172 24,462 Net loss per share - basic and diluted $ (0.12 ) $ (0.13 ) $ (0.26 ) $ (0.20 ) |
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share | The shares of the Company’s common stock issuable upon the exercise of stock options and vesting of restricted stock that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive are as follows: June 30, 2022 2021 Stock options 1,819,897 2,176,607 Restricted stock — 21,613 Total 1,819,897 2,198,220 |
Inventories (Tables)
Inventories (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Inventory Disclosure [Abstract] | |
Schedule of Current Inventory | June 30, 2022 December 31, 2021 Raw materials $ 2,549 $ 2,962 Work in process 218 173 Finished Goods 2,503 1,279 Inventory Gross 5,270 4,414 Inventory Reserve (269 ) (243 ) Inventory Net $ 5,001 $ 4,171 |
Leases Commitments (Tables)
Leases Commitments (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Components of Lease Expense | The Company has leases for office space and office equipment. The leases expire at various dates through 2028. Three Months Six Months Ended June 30, Ended June 30, Lease Cost Classification 2022 2022 Operating lease cost - Right of Use Asset Operating expenses $ 215 $ 430 Other information related to leases was as follows: Three Months Six Months Ended June 30, Ended June 30, 2022 202 2 Cash paid from operating cash flows for operating leases $ 236 $ 465 As of June 30, Weighted-average remaining lease term of operating leases (year s 5.7 Weighted-average discount rate for operating leases 7.4 % |
Summary of Detained Information of Lease Liabilities | Maturity of the Company’s lease liabilities as of June 30, 2022 was as follows: 2022 $ 467 2023 611 2024 642 2025 644 2026 664 2027 684 2028 172 Total lease payments 3,884 Less: imputed interest (720 ) Total lease liabilities 3,164 Less: current portion of lease liabilities (566 ) Long-term lease liabilities $ 2,598 |
Notes Payable (Table)
Notes Payable (Table) | 6 Months Ended |
Jun. 30, 2022 | |
Debt Disclosure [Abstract] | |
Summary of Interest Expense in Consolidated Income Statement | The following amounts are included in interest expense related to the Loan Agreement in the Company’s consolidated statement of operations for the three and six months ended June 30, 2022 and 2021: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Cash interest expense $ — $ 27 $ — $ 107 Accrual of notes payable final payment — 2 — 9 Amortization of debt costs — — — 13 Total interest expense $ — $ 29 $ — $ 129 |
Stockholders Equity (Tables)
Stockholders Equity (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values | Options granted under the Company’s stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Average risk-free interest rate 2.56% N/A 1.90% 0.20% Expected dividend yield None None None None Expected life 3.5 years 3.5 years 3.5 years 3.5 years Expected volatility 69.7% to 70.5% N/A 66.3% to 70.5% 66.0% to 66.0% Weighted average exercise price $5.19 N/A $5.22 $18.00 Weighted average fair value $1.72 N/A $2.46 $8.37 |
Stock-Based Compensation Expense Including Options and Restricted Stock by Category | The Company’s stock-based compensation expense, including options and restricted stock by category is as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Cost of revenue $ 1 $ 2 $ 1 $ 16 Engineering and product development 70 58 138 208 Marketing and sales 109 128 308 481 General and administrative 129 323 517 741 $ 309 $ 511 $ 964 $ 1446 |
Summary of Stock Option Activity for all Stock Option Plans | A summary of stock option activity for all stock option plans for the period ended June 30, 2022 is as follows: Number of Weighted Average Intrinsic Outstanding as of December 31, 2021 2,486,511 $ 9.27 $ 3,820 Granted 760,000 $ 5.22 $ 3 Exercised (28,833 ) $ 2.74 $ 75 Cancelled (479,797 ) $ 12.33 $ — Outstanding as of June 30, 2022 2,737,881 $ 7.68 $ 833 Options Exercisable as of December 31, 2021 1,619,855 $ 6.47 $ 3,730 Options Exercisable as of June 30, 2022 1,819,897 $ 7.44 $ 830 |
Segment Reporting (Tables)
Segment Reporting (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Segment Reporting [Abstract] | |
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss | The Company does not track its assets by operating segment and the CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Segment revenues: Detection $ 5,289 $ 4,789 $ 10,809 $ 10,508 Therapy 2,286 3,037 4,289 5,962 Total Revenue $ 7,575 $ 7,826 $ 15,098 $ 16,470 Segment gross profit: Detection $ 4,554 $ 4,005 $ 9,215 $ 8,730 Therapy 937 1,533 1,588 3,097 Segment gross profit $ 5,491 $ 5,538 $ 10,803 $ 11,827 Segment operating income (loss): Detection $ 446 $ 52 $ 1,068 $ 993 Therapy (797 ) (250 ) (2,006 ) (562 ) Segment operating income (loss): $ (351 ) $ (198 ) $ (938 ) $ 431 General, administrative, depreciation and amortization expense $ (2,763 ) $ (2,673 ) $ (5,698 ) $ (4,835 ) Interest expens e — (29 ) (1 ) (129 ) Interest income 14 19 16 33 Other expense (18 ) (13 ) (41 ) (37 ) Loss on extinguishment of debt — (386 ) — (386 ) Loss before income tax $ (3,118 ) $ (3,280 ) $ (6,662 ) $ (4,923 ) |
Basis of Presentation and Sig_3
Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - Segment | 6 Months Ended | 12 Months Ended |
Jun. 30, 2022 | Dec. 31, 2021 | |
Number of Operating Segments | 2 | |
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Europe [Member] | ||
Concentration Risk, Percentage | 8.60% | |
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | Europe [Member] | Revenue Through Exports [Member] | ||
Concentration Risk, Percentage | 39% |
Fair Value Measurements - Asset
Fair Value Measurements - Assets and Liabilities which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Assets | ||
Total Assets | $ 22,047 | $ 30,573 |
Money Market Accounts [Member] | ||
Assets | ||
Total Assets | 22,047 | 30,573 |
Level 1 [Member] | ||
Assets | ||
Total Assets | 22,047 | 30,573 |
Level 1 [Member] | Money Market Accounts [Member] | ||
Assets | ||
Total Assets | $ 22,047 | $ 30,573 |
Revenue - Revenues Disaggregate
Revenue - Revenues Disaggregated by Major Good or Service Line, Timing of Revenue Recognition, and Sales Channel, Reconciled to Our Reportable Segments (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | $ 7,575 | $ 7,826 | $ 15,098 | $ 16,470 |
Products [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 4,475 | 5,283 | 9,035 | 11,547 |
Service Contracts [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 2,183 | 1,996 | 4,226 | 3,894 |
Supply and Source Usage Agreements [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 367 | 529 | 780 | 1,010 |
Disposable Applicators [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 463 | 878 | ||
Other [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 87 | 18 | 179 | 19 |
Goods Transferred at a Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 5,002 | 5,300 | 10,147 | 11,565 |
Services Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 2,573 | 2,526 | 4,951 | 4,905 |
Direct Sales Force [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 4,208 | 4,440 | 7,918 | 8,989 |
OEM Partners [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 1,784 | 1,601 | 4,410 | 3,445 |
Channel Partners [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 1,583 | 1,785 | 2,770 | 4,036 |
Detection [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 5,289 | 4,789 | 10,809 | 10,508 |
Detection [Member] | Products [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 3,467 | 3,164 | 7,330 | 7,325 |
Detection [Member] | Service Contracts [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 1,822 | 1,625 | 3,479 | 3,183 |
Detection [Member] | Goods Transferred at a Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 3,455 | 3,164 | 7,335 | 7,325 |
Detection [Member] | Services Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 1,834 | 1,625 | 3,474 | 3,183 |
Detection [Member] | Direct Sales Force [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 3,505 | 3,188 | 6,399 | 7,063 |
Detection [Member] | OEM Partners [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 1,784 | 1,601 | 4,410 | 3,445 |
Therapy [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 2,286 | 3,037 | 4,289 | 5,962 |
Therapy [Member] | Products [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 1,008 | 2,119 | 1,705 | 4,222 |
Therapy [Member] | Service Contracts [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 361 | 371 | 747 | 711 |
Therapy [Member] | Supply and Source Usage Agreements [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 367 | 529 | 780 | 1,010 |
Therapy [Member] | Disposable Applicators [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 463 | 878 | ||
Therapy [Member] | Other [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 87 | 18 | 179 | 19 |
Therapy [Member] | Goods Transferred at a Point in Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 1,547 | 2,136 | 2,812 | 4,240 |
Therapy [Member] | Services Transferred over Time [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 739 | 901 | 1,477 | 1,722 |
Therapy [Member] | Direct Sales Force [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | 703 | 1,252 | 1,519 | 1,926 |
Therapy [Member] | Channel Partners [Member] | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from contracts with customers | $ 1,583 | $ 1,785 | $ 2,770 | $ 4,036 |
Revenue - Summary of Receivable
Revenue - Summary of Receivables, Contract Assets and Contract Liabilities from Contracts with Customers (Detail) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Contract with Customer, Asset and Liability [Abstract] | ||
Receivables, which are included in ‘Trade accounts receivable' | $ 10,171 | $ 8,891 |
Current contract assets, which are included in "Prepaid and other assets" | 1,399 | 1,895 |
Non-current contract assets, which are included in "other assets" | 0 | 844 |
Contract liabilities, which are included in "Deferred revenue" | $ 6,752 | $ 6,093 |
Revenue - Summary of Changes in
Revenue - Summary of Changes in Deferred Revenue from Contracts with Customers (Detail) $ in Thousands | 6 Months Ended |
Jun. 30, 2022 USD ($) | |
Deferred Revenue Disclosure [Abstract] | |
Balance at beginning of period | $ 6,093 |
Deferral of revenue | 6,333 |
Recognition of deferred revenue | (5,674) |
Balance at end of period | $ 6,752 |
Revenue - Additional Informatio
Revenue - Additional Information (Detail) $ in Millions | 12 Months Ended |
Dec. 31, 2021 USD ($) | |
Revenue From Contract With Customer [Line Items] | |
Unearned amount to recognize in 2022 | $ 4.6 |
Unearned amount to recognize in 2023 | 3.5 |
Unearned amount to recognize in 2024 | 1.3 |
Unearned amount to recognize in 2025 | 1.1 |
Unearned amount to recognize in 2025, and thereafter | $ 0.1 |
Net Loss per Common Share - Cal
Net Loss per Common Share - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] | ||||
Net loss | $ (3,118) | $ (3,280) | $ (6,663) | $ (4,923) |
Shares used in the calculation of basic and diluted net loss per share | 25,185 | 24,989 | 25,172 | 24,462 |
Earnings Per Share, Basic | $ (0.12) | $ (0.13) | $ (0.26) | $ (0.2) |
Earnings Per Share, Diluted | $ (0.12) | $ (0.13) | $ (0.26) | $ (0.2) |
Net Loss per Common Share - Sch
Net Loss per Common Share - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock options, warrants and restricted stock | 1,819,897 | 2,198,220 |
Stock Options [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock options, warrants and restricted stock | 1,819,897 | 2,176,607 |
Restricted Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Common stock options, warrants and restricted stock | 0 | 21,613 |
Inventory - Schedule of Current
Inventory - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 2,549 | $ 2,962 |
Work in process | 218 | 173 |
Finished Goods | 2,503 | 1,279 |
Inventory Gross | 5,270 | 4,414 |
Inventory Reserve | (269) | (243) |
Inventory | $ 5,001 | $ 4,171 |
Inventory - Additional Informat
Inventory - Additional Information (Detail) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Inventory reserve | $ 269 | $ 243 |
Goodwill - Additional Informati
Goodwill - Additional Information (Detail) $ in Thousands | 6 Months Ended |
Jun. 30, 2022 USD ($) | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill Impairment | $ 0 |
Leases Commitments - Schedule o
Leases Commitments - Schedule of Components of Lease Expense (Detail) - Accounting Standards Update 2016-02 [Member] $ in Thousands | 3 Months Ended | 6 Months Ended |
Jun. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | |
Lessee, Lease, Description [Line Items] | ||
Operating lease cost—Right of Use Asset | $ 215 | $ 430 |
Cash paid from operating cash flows for operating leases | $ 236 | $ 465 |
Weighted-average remaining lease term of operating leases (years) | 5 years 8 months 12 days | 5 years 8 months 12 days |
Weighted-average discount rate for operating leases | 7.40% | 7.40% |
Leases Commitments - Summary of
Leases Commitments - Summary of Detained Information of Lease Liabilities (Detail) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
2022 | $ 467 | |
2023 | 611 | |
2024 | 642 | |
2025 | 644 | |
2026 | 664 | |
2027 | 684 | |
2028 | 172 | |
Total lease payments | 3,884 | |
Less: imputed interest | (720) | |
Total lease liabilities | 3,164 | |
Less: current portion of lease liabilities | (566) | |
Long-term lease liabilities | $ 2,598 | $ 266 |
Leases Commitments - Additional
Leases Commitments - Additional Information (Detail) - USD ($) | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2022 | |
Lessee, Lease, Description [Line Items] | |||
Increase in right of use asset | $ 2,400,000 | ||
Irvine Amendment [Member] | |||
Lessee, Lease, Description [Line Items] | |||
Lessee Operating Lease Option To Extend | 5 years, or until March of 2028 | ||
Monthly Rent As per Square Foot | $ 2,100 | ||
Annual Increase In Rent As Per Square Foot Year Two | $ 60 | ||
Annual Increase In Rent As Per Square Foot Year Three | $ 70 |
Notes Payable - Summary of Inte
Notes Payable - Summary of Interest Expense in Consolidated Income Statement (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Interest Expense [Line Items] | ||||
Total interest expense | $ 0 | $ 29 | $ 1 | $ 129 |
Western Alliance Bank [Member] | ||||
Interest Expense [Line Items] | ||||
Cash interest expense | 0 | 27 | 0 | 107 |
Accrual of notes payable final payment | 0 | 2 | 0 | 9 |
Amortization of debt costs | 0 | 0 | 0 | 13 |
Total interest expense | $ 0 | $ 29 | $ 0 | $ 129 |
Notes Payable - Additional Info
Notes Payable - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Apr. 27, 2021 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Mar. 30, 2020 | |
Debt Instrument [Line Items] | |||||
Repayments of Lines of Credit | $ 7,354,283 | ||||
Gain (Loss) on Extinguishment of Debt | $ (386) | $ 0 | $ (386) | ||
Western Alliance Bank [Member] | |||||
Debt Instrument [Line Items] | |||||
Gain (Loss) on Extinguishment of Debt | 386,000 | ||||
Western Alliance Bank [Member] | Debt Prepayment Cost [Member] | |||||
Debt Instrument [Line Items] | |||||
Debt prepayment cost | 140,000 | ||||
Western Alliance Bank [Member] | Final Payment Of Loan [Member] | |||||
Debt Instrument [Line Items] | |||||
Final Payment of Loan | 122,000 | ||||
Western Alliance Bank [Member] | Termination Loans [Member] | |||||
Debt Instrument [Line Items] | |||||
Termination Loans | 65,000 | 65,000 | |||
Western Alliance Bank [Member] | Unamortized Debt Issuance Expense [Member] | |||||
Debt Instrument [Line Items] | |||||
Unamortized closing costs | $ 58,000 | $ 58,000 | |||
Term Loan A [Member] | Western Alliance Bank [Member] | |||||
Debt Instrument [Line Items] | |||||
Credit facility | $ 7,000 | ||||
Revolving Credit Facility [Member] | Western Alliance Bank [Member] | |||||
Debt Instrument [Line Items] | |||||
Credit facility | $ 5,000 |
Stockholders Equity - Options G
Stockholders Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - $ / shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Weighted average exercise price | $ 5.22 | |||
Stock Options [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Average risk-free interest rate | 2.56% | 1.90% | 0.20% | |
Expected dividend yield | 0% | 0% | 0% | 0% |
Expected life | 3 years 6 months | 3 years 6 months | 3 years 6 months | 3 years 6 months |
Weighted average exercise price | $ 5.19 | $ 5.22 | $ 18 | |
Weighted average fair value | $ 1.72 | $ 2.46 | $ 8.37 | |
Minimum [Member] | Stock Options [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expected volatility | 69.70% | 66.30% | 66% | |
Maximum [Member] | Stock Options [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expected volatility | 70.50% | 70.50% | 66% |
Stockholders Equity - Stock-Bas
Stockholders Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Allocated share-based compensation expense | $ 309 | $ 511 | $ 964 | $ 1,446 |
Cost of Revenue [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Allocated share-based compensation expense | 1 | 2 | 1 | 16 |
Engineering and Product Development [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Allocated share-based compensation expense | 70 | 58 | 138 | 208 |
Marketing and Sales [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Allocated share-based compensation expense | 109 | 128 | 308 | 481 |
General and Administrative Expense [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Allocated share-based compensation expense | $ 129 | $ 323 | $ 517 | $ 741 |
Stockholders Equity - Additiona
Stockholders Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | |||
Mar. 02, 2021 | Dec. 31, 2019 | Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of option Granted | 760,000 | |||||
Common stock, Issued | 28,833 | |||||
Net proceeds from Issue of common stock | $ 0 | $ 23,229 | ||||
Underwritten public offering shares | 1,393,738 | |||||
Offering price, per share | $ 18 | |||||
Gross proceeds from sale of units | $ 25,100 | |||||
Net proceeds from sale of units | $ 23,200 | |||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 2,800 | $ 2,800 | ||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 11 months 1 day | |||||
Restricted Stock [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of option Granted | 0 | 0 | 0 | 22,488 | ||
Number of shares vested | 0 | 0 | ||||
Intrinsic value of restricted shares that vested | $ 0 | $ 0 | ||||
Stock Options [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Common stock, Issued | 6,000 | 28,833 | ||||
Net proceeds from Issue of common stock | $ 13,000 | $ 79,000 | ||||
2019 Employee Stock Purchase Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Percentage of voting power | 5% | |||||
Description of employee stock purchase plan | Employees who participate in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of their base compensation during an accumulation period. Unless the participating employee withdraws from participation, accumulated payroll deductions are used to purchase shares of common stock on the last business day of the accumulation period (the “Purchase Date”) at a price equal to 85% of the lower of the fair market value on (i) the Purchase Date or (ii) the first day of such accumulation period. Under applicable tax rules, no employee may purchase more than $25,000 worth of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. | |||||
Number of shares issued, Employee Stock Purchase Plans | 950,000 | 8,683 | 18,064 | |||
Stock-based compensation expense | $ 12,000 | $ 22,000 | ||||
Employee-related Liabilities, Current | $ 34,000 | $ 34,000 | ||||
Black Scholes Model [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of option Granted | 85,000 | 760,000 |
Stockholders Equity - Summary o
Stockholders Equity - Summary of Stock Option Activity for all Stock Option plan (Detail) $ / shares in Units, $ in Thousands | 6 Months Ended | |
Jun. 30, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | |
Share-based Payment Arrangement [Abstract] | ||
Beginning balance | shares | 2,486,511 | |
Granted | shares | 760,000 | |
Exercised | shares | (28,833) | |
Cancelled | shares | (479,797) | |
Ending Balance | shares | 2,737,881 | |
weighted Average, Beginning Balance | $ / shares | $ 9.27 | |
Granted | $ / shares | 5.22 | |
Exercised | $ / shares | 2.74 | |
Cancelled | $ / shares | 12.33 | |
Weighted Average, Ending Balance | $ / shares | $ 7.68 | |
Intrinsic Value, Beginning Balance | $ | $ 3,820 | |
Granted | $ | 3 | |
Exercised | $ | 75 | |
Intrinsic Value, Ending Balance | $ | $ 833 | |
Exercisable, Number of Options | shares | 1,819,897 | 1,619,855 |
Exerciable, Weighted Average Exercise Price | $ / shares | $ 7.44 | $ 6.47 |
Exercisable, Intrinsic Value | $ | $ 830 | $ 3,730 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Detail) | Jun. 30, 2022 USD ($) |
Schedule Of Income Tax Expense [Line Items] | |
Unrecognized tax benefits | $ 0 |
Deferred Tax Liabilities, Goodwill | $ 5,100 |
Segment Reporting - Summary of
Segment Reporting - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Segment revenues: | ||||
Total Revenue | $ 7,575 | $ 7,826 | $ 15,098 | $ 16,470 |
Segment gross profit: | ||||
Segment gross profit | 5,491 | 5,538 | 10,803 | 11,827 |
Segment operating income (loss): | ||||
Segment operating income (loss) | (351) | (198) | (938) | 431 |
General, administrative, depreciation and amortization expense | (2,763) | (2,673) | (5,698) | (4,835) |
Interest expense | 0 | (29) | (1) | (129) |
Interest income | 14 | 19 | 16 | 33 |
Other income | (18) | (13) | (41) | (37) |
Loss on extinguishment of debt | (386) | 0 | (386) | |
Loss before provision for income taxes | (3,118) | (3,280) | (6,662) | (4,923) |
Product [Member] | ||||
Segment revenues: | ||||
Total Revenue | 4,475 | 4,552 | 9,035 | 10,109 |
Service [Member] | ||||
Segment revenues: | ||||
Total Revenue | 3,100 | 3,274 | 6,063 | 6,361 |
Detection [Member] | ||||
Segment gross profit: | ||||
Segment gross profit | 4,554 | 4,005 | 9,215 | 8,730 |
Segment operating income (loss): | ||||
Segment operating income (loss) | 446 | 52 | 1,068 | 993 |
Detection [Member] | Product [Member] | ||||
Segment revenues: | ||||
Total Revenue | 5,289 | 4,789 | 10,809 | 10,508 |
Therapy [Member] | ||||
Segment gross profit: | ||||
Segment gross profit | 937 | 1,533 | 1,588 | 3,097 |
Segment operating income (loss): | ||||
Segment operating income (loss) | (797) | (250) | (2,006) | (562) |
Therapy [Member] | Service [Member] | ||||
Segment revenues: | ||||
Total Revenue | $ 2,286 | $ 3,037 | $ 4,289 | $ 5,962 |
Segment Reporting - Additional
Segment Reporting - Additional Information (Detail) | 6 Months Ended |
Jun. 30, 2022 customer | |
Schedule Of Geographical Information [Line Items] | |
Number of reporting segments | 2 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) $ in Millions | Jun. 30, 2022 USD ($) |
Schedule Of Leases [Line Items] | |
Purchase obligations to suppliers for future product deliverables | $ 5.1 |
Minimum royalty obligations | $ 0.2 |